News

Are you interested in learning how to promote your dermatology practice on Twitter? Compared to other social networks, Twitter is one of the simplest and most straightforward platforms you could ever use.

Purpura, whether after trauma or an aesthetic procedure, is undesirable to patients. The ecchymoses can last for up to two weeks, and dyspigmentation can persist even longer.

Kent Remington, M.D., guides patients through his method for conducting a successful aesthetic consult, he told attendees at the MauiDerm 2014 meeting. Knowing a patient’s “real” reasons for aesthetic improvement - and shifting from a monotherapy toward performing a full-face rejuvenation following a multitherapeutic approach - are essential in achieving excellent aesthetic outcomes, he told attendees at the MauiDerm 2014 meeting.

We’re learning more about the aging process and how it occurs at different levels: from the surface of the skin, all the way down to the bony structure. Our purpose in aesthetics is to understand this process and to work with it to highlight the natural beauty of an individual, Ava Shamban, M.D., told attendees at the MauiDerm 2014 meeting.

Couldn't make it to MauiDerm 2014? Here is a brief collection of some of the poster presentations from the conference.

Michael Gold, M.D., at the MauiDerm 2014 conference shared his insight into the world of fake botulinum toxins. There is a huge counterfeit market, and it behooves dermatologists to be aware, because the products are easily acquired over the Internet or purchased overseas and carried into the United States.

Joel Cohen, M.D., explained to attendees at MauiDerm 2014 the differences among the three approved botulinum toxin products and how to use them successfully to take advantage of their unique properties. He recommended that doctors really think about these products as unique and begin to use them for their individual properties.

New drugs, data and guidelines on acne and rosacea treatment were among the takeaways from days two and three of MauiDerm 2014. Presenters also described evidence-based suggestions for managing pigmentary disorders and updated information on infectious diseases.

A multispectral digital skin lesion analysis device may be useful in helping clinicians to classify clinically ambiguous lesions, detect early melanomas in young adults, and identify outlier lesions that should be biopsied, according to a collection of posters presented at MauiDerm 2014.

At the MauiDerm 2014 meeting, conference organizer George Martin, M.D., shared five clinical pearls for treating facial actinic keratosis (AK).

Nutraceuticals and the claims that these products make have become increasingly popular on a global basis, according to an expert who spoke at MauiDerm 2014.

Dermatologists report high job satisfaction and are among the most likely of all specialties to take dietary supplements, a recent report suggests.

Topical hydration can reduce thermal damage to skin treated with a plasma skin regeneration (PSR) device, according to a recent study.

Results of a new study show that laser and other light-based therapies show potential as a treatment for onychomycosis.

The MauiDerm 2014 meeting kicked off Sunday with a Hawaiian blessing led by the conference's organizer, George Martin, M.D., Dermatology and Laser Center of Maui, Kihei, Hawaii.

In an effort to learn more about patients’ experiences with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome, researchers have developed two new questionnaires to evaluate and assess the effects of the diseases.

The Food and Drug Administration has approved GlaxoSmithKline’s Mekinist (trametinib) for use in combination with Tafinlar (dabrafenib) as a possible treatment for patients suffering from inoperable melanoma and certain types of metastatic melanoma.

Valeant Pharmaceuticals has partnered with a beauty company to create aesthetic products, beginning with a technology that reshapes the appearance of the skin.

Dermoscopy can be a useful and reliable tool to differentiate between superficial basal cell carcinoma and other basal cell carcinoma subtypes, according to a recent study.

There are more tanning facilities than McDonald’s restaurants in the state of Florida, according to recent research.

A Massachusetts dermatology practice has agreed to pay a $150,000 settlement to the federal government, the result of an unencrypted thumb drive containing patient data being stolen from a staff member’s car.

An analysis of 60 papers related to skin ulcer treatment suggests that the research presented in the majority of the papers is flawed, leading to unreliable results.

Common gastrointestinal side effects to methotrexate may include anticipatory, associative and behavioral symptoms, aside from post-treatment nausea and vomiting, according to a new report.

The implementation of next generation technologies coupled with the acquisition of a more in-depth knowledge of dermatologic diseases and conditions are proving to be very helpful in better treating and managing patients.

While government funds for research in dermatology and other medical specialties seems to be dwindling, there are forces at work that could help to pick up at least part of the slack.

The landscape of dermatology is rapidly changing and every practicing dermatolo-gist will almost certainly be affected. Dermatology Times asked Dirk Elston, M.D., president of the American Academy of Dermatology, to address some of these issues so that we may all have a better idea of what lies ahead for our specialty.

The American Academy of Dermatology has joined the Choosing Wisely campaign, recently releasing its list of five specific tests or procedures that are commonly performed but are not always necessary and might even cause harm.

Over the decades, many highly useful treatment modalities have been developed which have greatly improved the lives of our patients. However, many additional therapies with questionable usefulness have also become part of our treatment armamentarium.

Recent head-to-head clinical trial results with secukinumab (Novartis) and etanercept (Enbrel, Amgen) show a significant superiority of secukinumab in the treatment and management of patients with moderate-to-severe plaque psoriasis, perhaps heralding a new standard of care for this patient population.

Alone or in combination with other lasers, the picosecond laser can treat a variety of cosmetic concerns including tattoos, scars and striae, an expert says.